- Home
- SLAI vs PRPO Comparison
SLAI vs PRPO Comparison
Compare SLAI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLAI
- PRPO
- Stock Information
- Founded
- SLAI 2001
- PRPO N/A
- Country
- SLAI United States
- PRPO United States
- Employees
- SLAI N/A
- PRPO N/A
- Industry
- SLAI EDP Services
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- SLAI Technology
- PRPO Industrials
- Exchange
- SLAI Nasdaq
- PRPO Nasdaq
- Market Cap
- SLAI 39.4M
- PRPO 32.4M
- IPO Year
- SLAI N/A
- PRPO N/A
- Fundamental
- Price
- SLAI $1.51
- PRPO $19.50
- Analyst Decision
- SLAI
- PRPO
- Analyst Count
- SLAI 0
- PRPO 0
- Target Price
- SLAI N/A
- PRPO N/A
- AVG Volume (30 Days)
- SLAI 182.3K
- PRPO 10.7K
- Earning Date
- SLAI 11-19-2025
- PRPO 11-14-2025
- Dividend Yield
- SLAI N/A
- PRPO N/A
- EPS Growth
- SLAI N/A
- PRPO N/A
- EPS
- SLAI N/A
- PRPO N/A
- Revenue
- SLAI $24,576,000.00
- PRPO $22,800,000.00
- Revenue This Year
- SLAI $14.32
- PRPO N/A
- Revenue Next Year
- SLAI N/A
- PRPO N/A
- P/E Ratio
- SLAI N/A
- PRPO N/A
- Revenue Growth
- SLAI N/A
- PRPO 30.95
- 52 Week Low
- SLAI $1.22
- PRPO $3.90
- 52 Week High
- SLAI $8.07
- PRPO $22.38
- Technical
- Relative Strength Index (RSI)
- SLAI N/A
- PRPO 47.30
- Support Level
- SLAI N/A
- PRPO $19.00
- Resistance Level
- SLAI N/A
- PRPO $21.00
- Average True Range (ATR)
- SLAI 0.00
- PRPO 1.09
- MACD
- SLAI 0.00
- PRPO -0.22
- Stochastic Oscillator
- SLAI 0.00
- PRPO 21.96
About SLAI SOLAI Limited American Depositary Shares (each representing one hundred (100) Class A Ordinary Shares)
SOLAI Ltd is a cryptocurrency mining company. The company aims to build a comprehensive blockchain-based ecosystem that includes AI, stablecoins, payment infrastructure, and Solana treasury and staking operations.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.